Compare

CJC-1295 vs Follistatin 344

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CJC-1295

670 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-59
Recovery
-110
Digestive comfort
-71
Skin appearance
1
Appetite control
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-143
Anxiety
-30
Flushing
-106
Headache
-3
GI discomfort
-103

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
11
0.4–0.6 mg
21
0.6–1 mg
15
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing34stacking27side effects30cjc-129528

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 147 repeat reporters

Follistatin 344

1071 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 44% · Unfavorable overall 11%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
114
Digestive comfort
24
Skin appearance
58
Appetite control
152
Energy
119

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
30
Flushing
104
Headache
23
GI discomfort
148
Dizziness
119

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
3
0.4–0.6 mg
9
0.6–1 mg
20
1–2 mg
10
2–3 mg
2
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing35stacking23side effects11follistatin 34429

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 20 days · Based on 236 repeat reporters

Sources (8)

Published sources linked on the CJC-1295 and Follistatin 344 wiki pages.

  1. PubMed

    Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  2. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    CJC-1295 growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

    Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Follistatin / Myostatin inhibition studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis

    Sugiyama M, Yamaki A, Furuya M, et al. American Journal of Physiology — Endocrinology and Metabolism. 2010

    Source
    Wiki study page →
  7. PubMed

    Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy

    Sepulveda PV, Bush ED, Bhattacharya A, et al. Scientific Reports. 2015

    Source
    Wiki study page →
  8. PubMed

    The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation

    Stefanakis K, Kokkorakis M, Mantzoros CS. Metabolism: clinical and experimental. 2024

    Source
    Wiki study page →